|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
679400050
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
ºÒÅõ¸í ÇÃ¶ó½ºÆ½ ¿ë±â¿¡ ´ã±ä ¹«»öÀÇ ¸¼Àº ¼ö¿ë¼º ¾×Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
Á¦Á¶¿ø |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 3¹Ð¸®¸®ÅÍ |
1 °³ |
º´ |
8806794000507 |
8806794000514 |
|
|
| ÁÖ¼ººÐÄÚµå |
461301CLQ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
È¿´ÉÈ¿°úÈ¿´ÉÈ¿°ú
¼Ó´«½ç °¨¸ðÁõ
¾÷µ¥ÀÌÆ®ÀÏ:2009-11-10/ ¾÷µ¥ÀÌÆ®Á¾·ù:¼ö½Ã¾÷µ¥ÀÌÆ®
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¿ë¹ý¿ë·®¿ë¹ý¿ë·®
1. 1ÀÏ 1ȸ, ¸ÅÀÏ Àú³á, ÄÜÅÃÆ®·»Áî ¹× ÈÀåÀ» Á¦°ÅÇÏ°í ±ú²ýÀÌ ¼¼¾ÈÇÑ ÈÄ Ã·ºÎµÈ ºÀ¿¡ ÀÌ ¾à ÇÑ ¹æ¿ïÀ» ¹¯Çô ¼Ó´«½çÀÌ ³ À ´«²¨Ç® °¡ÀåÀÚ¸® ÇǺο¡ ÃÖ¼Ò 8ÁÖµ¿¾È ±ÕµîÈ÷ Á÷Á¢ ¹Ù¸¥´Ù. À̶§, ¼Ó´«½çÀÌ ÀÚ¶ó´Â ºÎÀ§ À ´«²¨Ç®¿¡ ¾à°£ ÃËÃËÇÑ ´À³¦ÀÌ µé°í, ¾×ü°¡ È帣Áö ¾ÊÀ» Á¤µµ·Î ¹Ù¸¥´Ù. 2. 1ÀÏ 1ȸ¸¦ ÃʰúÇÏÁö ¾Ê´Â´Ù. 3. ´«²¨Ç® °¡ÀåÀÚ¸® ¹Ù±ùÂÊÀ¸·Î Èê·¯³ª¿À´Â ³²Àº ¿ë¾×ÀÇ °æ¿ì, ÈÀåÁö ¶Ç´Â ¼ö°Ç µîÀ» ÀÌ¿ëÇÏ¿© Á¦°ÅÇÑ´Ù. 4. ¾Æ·¡ÂÊ ¼Ó´«½ç ¶óÀο¡´Â ¹Ù¸£Áö ¾Ê´Â´Ù. ÀÌ ¾àÀ» Ãß°¡·Î ¹Ù¸£´Â °ÍÀº ¼Ó´«½ç ¼ºÀåÀ» Áõ°¡½ÃŰÁö ¾Ê´Â´Ù. 5. ÷ºÎµÈ ºÀÀº ÇÑÂÊ ´«²¨Ç®¿¡ »ç¿ë ÈÄ ¹ö¸®°í, »õ·Î¿î ¸ê±ÕºÀÀ» ÀÌ¿ëÇØ ¹Ý´ëÂÊ ´«²¨Ç®¿¡ ¹Ù¸¥´Ù. ºÀÀº Àç»ç¿ëÇÏÁö ¾ÊÀ¸¸ç ÷ºÎµÈ ºÀ ¿ÜÀÇ ´Ù¸¥ ºÀÀº »ç¿ëÇÏÁö ¾Ê´Â´Ù.
¾÷µ¥ÀÌÆ®ÀÏ:2009-11-10/ ¾÷µ¥ÀÌÆ®Á¾·ù:¼ö½Ã¾÷µ¥ÀÌÆ®
|
| ±Ý±â |
1) ºñ¸¶ÅäÇÁ·Î½ºÆ®, ¿°Èº¥ÀßÄÚ´½ ¹× ´Ù¸¥ ¼ººÐ¿¡ ´ëÇØ °ú¹ÎÁõÀÌ Àִ ȯÀÚ
2) 18¼¼ ¹Ì¸¸¿¡´Â »ç¿ëÇÏÁö ¸» °Í
¾÷µ¥ÀÌÆ®ÀÏ:2009-11-10/ ¾÷µ¥ÀÌÆ®Á¾·ù:¼ö½Ã¾÷µ¥ÀÌÆ®
|
| ½ÅÁßÅõ¿© |
1) Ȱµ¿¼º ¾È³»¿°À» °¡Áø ȯÀÚ(¿°ÁõÀÌ ¾Ç鵃 ¼ö ÀÖÀ½)
2) ¹«¼öÁ¤Ã¼Áõ ȯÀÚ¿Í ¾È³»¿¡ ·»Á »ðÀÔÇÑ °¡¼º¹«¼öÁ¤Ã¼ÁõȯÀÚ ¹× Ȳ¹ÝºÎÁ¾ À§ÇèÀÎÀÚ¸¦ °¡Áø ȯÀÚ(Áõ°¡µÈ ¾È¾ÐÀ» À§ÇÑ ºñ¸¶ÅäÇÁ·Î½ºÆ® Á¡¾È¾× Ä¡·á ½Ã, ³¶Æ÷¼º Ȳ¹ÝºÎÁ¾À» Æ÷ÇÔÇÑ È²¹ÝºÎÁ¾ÀÌ º¸°íµÇ¾úÀ½)
3) °³¹æ°¢³ì³»Àå ¹× °í¾È¾ÐÁõ Ä¡·á½Ã ¾È¾ÐÀúÇϸ¦ ¸ñÀûÀ¸·Î ÇÏ´Â ÇÁ·Î½ºÅ¸±Û¶õµòÁ¦Á¦¸¦ »ç¿ëÇϴ ȯÀÚ
4) ÀӺΠ¹× ¼öÀ¯ºÎ
¾÷µ¥ÀÌÆ®ÀÏ:2009-11-10/ ¾÷µ¥ÀÌÆ®Á¾·ù:¼ö½Ã¾÷µ¥ÀÌÆ®
|
| ÀÌ»ó¹ÝÀÀ |
´ÙÀ½Àº 278¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î 4°³¿ù °£ ½ÃÇàÇÑ ´Ù±â°ü, ÀÌÁ߸ͰË, ¹«ÀÛÀ§, À§¾àÁ¶Àý, ÆòÇü¿¬±¸ ÀÓ»ó½ÃÇè ¿¬±¸ °á°ú¿¡ ±âÃÊÇÑ´Ù.
°¡Àå ºó¹øÇÏ°Ô º¸°íµÈ À¯ÇعÝÀÀÀº ´« °¡·Á¿òÁõ(3.6%), °á¸·ÃæÇ÷(3.6%), ÇǺΠ»ö¼ÒÄ§Âø(2.8%), °Ë¿¹Ý(2.2%), ¾È±¸ÀÚ±Ø, ¾È±¸ °ÇÁ¶, ´«²¨Ç® È«¹Ý µîÀ̸ç, ȯÀÚÀÇ 4% ÀÌÇÏ¿¡¼ ¹ß»ýÇÏ¿´´Ù.
»ó½ÂµÈ ¾È¾ÐÀ» °¨¼Ò½Ã۱â À§ÇØ ºñ¸¶ÅäÇÁ·Î½ºÆ® Á¡¾È¾×À» »ç¿ë ½Ã º¸°íµÈ ¹ÝÀÀÀº °á¸·ÃæÇ÷, ´«°¡·Á¿òÁõ, ¾È±¸°ÇÁ¶, ½Ã°¢Àå¾Ö, ¾È±¸ÀÛ¿°¨, À̹°°¨, ¾È±¸ÅëÁõ, ¾È°Ë¿°, ¹é³»Àå, Ç¥À缺 Á¡¼º °¢¸·¿°, ´« ºÐºñ¹° Áõ°¡, ´«¹°, ´«ºÎ½É, ¾Ë·¹¸£±â¼º °á¸·¿°, ¾ÈÁ¤ÇÇ·Î, ȫä»ö¼ÒÄ§Âø Áõ°¡, °á¸·ºÎÁ¾, ÀÌ»óü¸ð¼ºÀå, ȫä¿°, °¨¿°(ÁÖ·Î °¨±â ¹× »ó±âµµ°ü °¨¿°), µÎÅë, ¹«·ÂÁõ µîÀ̾ú´Ù.
¾÷µ¥ÀÌÆ®ÀÏ:2009-11-10/ ¾÷µ¥ÀÌÆ®Á¾·ù:¼ö½Ã¾÷µ¥ÀÌÆ®
|
| »óÈ£ÀÛ¿ë |
ÀÌ ¾à°ú µ¿ÀÏ ÁÖ¼ººÐÀ» Æ÷ÇÔÇÑ ºñ¸¶ÅäÇÁ·Î½ºÆ® Á¡¾È¾×ÀÇ °æ¿ì, ¾È±¸ ¿ë·®¿¡¼ ºñ¸¶ÅäÇÁ·Î½ºÆ®ÀÇ Àü½Å ³óµµ°¡ ¸Å¿ì ³·±â ¶§¹®¿¡(0.2ng/mL ÀÌÇÏ), »ç¶÷¿¡¼ ¾à¹° »óÈ£ÀÛ¿ëÀÌ ¿¹»óµÇÁö ¾Ê´Â´Ù. ºñÀÓ»ó½ÃÇè¿¡¼ ºñ¸¶ÅäÇÁ·Î½ºÆ®´Â ´Ù¾çÇÑ Á¾·ùÀÇ È¿¼Ò¿Í °æ·Î¿¡ ÀÇÇØ ´ë»çµÇ¸ç °£ÀÇ ¾à¹° ´ë»ç È¿¼Ò°è¿¡ ¿µÇâÀÌ ¾ø¾ú´Ù. ±×·¯¹Ç·Î ´Ù¸¥ ¾à¹°°úÀÇ »óÈ£ÀÛ¿ëÀº ¿¬±¸µÇÁö ¾Ê¾Ò´Ù.
¾÷µ¥ÀÌÆ®ÀÏ:2009-11-10/ ¾÷µ¥ÀÌÆ®Á¾·ù:¼ö½Ã¾÷µ¥ÀÌÆ®
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Á¦Çüº° º¹¾àÁöµµ |
[Á¡¾È¾×] |
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Bimatoprost¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Bimatoprost reduces the pressure in the eye by mimicking the action of a naturally-occuring prostaglandin. Prostaglandins are a group of chemicals found in many places in the body. In the eye, they increase the drainage of the aqueous humour out of the eyeball. Bimatoprost is a synthetic compound related to one of the natural prostaglandins, and works by increasing the drainage of aqueous humour out of the eyeball. This decreases the pressure within the eye.
|
| Pharmacology |
Bimatoprost¿¡ ´ëÇÑ Pharmacology Á¤º¸ Bimatoprost is a prostamide, a synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost lowers intraocular pressure (IOP) in humans. Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
|
| Absorption |
Bimatoprost¿¡ ´ëÇÑ Absorption Á¤º¸ Systemically absorbed when administered to the eye.
|
| Pharmacokinetics |
BimatoprostÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÃÖ°í³óµµ µµ´Þ½Ã°£ : ¾È¾àÀÇ °æ¿ì - 10ºÐ
- Èí¼ö : ¾È±¸ Á¡Àû½Ã Ç÷Áß ³óµµ´Â 0.1 ng/mL ÀÌÇÏ·Î ³·À½
- ºÐÆ÷ : ´Ü¹é°áÇÕ·ü 88%, ºÐÆ÷ ¿ëÀû 0.7 L/kg
- ´ë»ç : °£¿¡¼ ´ë»çµÇ¸ç ±× Á¤µµ´Â ¹àÇôÁ® ÀÖÁö ¾ÊÀ½
- ¹è¼³ : 67% ½ÅÀåÀ» ÅëÇÑ ¹è¼³, 25% ´ëº¯À¸·Î ¹è¼³
- ¹Ý°¨±â : 45ºÐ
|
| Toxicity |
Bimatoprost¿¡ ´ëÇÑ Toxicity Á¤º¸ In oral (by gavage) mouse and rat studies, doses up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m2 is at least 70 times higher than the accidental dose of one bottle of bimatoprost for a 10 kg child.
|
| Drug Interactions |
Bimatoprost¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Bimatoprost¿¡ ´ëÇÑ Description Á¤º¸ Bimatoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. It binds to the prostanoid FP receptor.
|
| Drug Category |
Bimatoprost¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antiglaucomic AgentsAntihypertensive Agents
|
| Smiles String Canonical |
Bimatoprost¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCNC(=O)CCCC=CCC1C(O)CC(O)C1C=CC(O)CCC1=CC=CC=C1
|
| Smiles String Isomeric |
Bimatoprost¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1
|
| InChI Identifier |
Bimatoprost¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1/f/h26H
|
| Chemical IUPAC Name |
Bimatoprost¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-11-03
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|